Ownership signal CIK-linked ownership evidence from parsed SEC filings. 2 signals
Large-stake signal

Form

SCHEDULE 13D/A

Active or control-oriented beneficial ownership filing.

Ownership

12%

Beneficial ownership of this reported class.

Shares

5,243,421 shares

Shares beneficially owned as disclosed.

Event date

06 Aug 2026

Date tied to the ownership event or amendment.

Accepted by SEC

10 Aug 2026

EDGAR acceptance date.

How to read this large-stake filing
  • Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
  • Compare this filing with the holder history and issuer page before treating the percentage as a current position.
  • Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
Subject security Names, identifiers, and filing context for this profile. 2 source fields
Symbol
MBX
Shares outstanding
44,815,564 shares
Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
SCHEDULE 13D/A
Accepted by SEC
10 Aug 2026, 17:35:46 UTC
Event date
06 Aug 2026
Prior SEC filing
30 Sep 2025
Source filing
View source filing

Key filing fact

Frazier Life Sciences Public Fund, L.P. disclosed 12% ownership in MBX BIOSCIENCES, INC. Common Stock, $0.0001 par value per share (MBX) on 06 Aug 2026.

Key facts

  • Frazier Life Sciences Public Fund, L.P. filed SCHEDULE 13D/A for MBX BIOSCIENCES, INC. Common Stock, $0.0001 par value per share (MBX).
  • Disclosed ownership: 12%.
  • Date of event: 06 Aug 2026.

Change

  • Previous schedule filing date: 30 Sep 2025.
  • Current filing was accepted on 10 Aug 2026, 17:35.

Research use

  • This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
  • Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.

Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

View source filing

Reporting persons

Disclosed reporting parties (11)

Names, ownership percentages, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.

Name Ownership Shares owned Sole voting power Shared voting power Signature Title CIK
Frazier Life Sciences Public Fund, L.P. 3% 1,429,573 0 1,429,573 /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P., GP of Frazier Life Sciences Public Fund, L.P. 0001863769
FHMLSP, L.P. 3% 1,429,573 0 1,429,573 /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P. 0001879466
FHMLSP, L.L.C. 3% 1,429,573 0 1,429,573 /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLSP, L.L.C. 0001879465
Frazier Life Sciences X, L.P. 11% 5,219,440 0 5,219,440 /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P., GP of Frazier Life Sciences X, L.P. 0001790879
FHMLS X, L.P. 11% 5,219,440 0 5,219,440 /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P. 0001790880
FHMLS X, L.L.C. 11% 5,219,440 0 5,219,440 /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLS X, L.L.C. 0001790811
Frazier Life Sciences XI, L.P. 0% 3,000 0 3,000 /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P., GP of Frazier Life Sciences XI, L.P. 0001911592
FHMLS XI, L.P. 0% 3,000 0 3,000 /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P. 0001911580
FHMLS XI, L.L.C. 0% 3,000 0 3,000 /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLS XI, L.L.C. 0001911623
James N. Topper 12% 5,219,440 0 5,219,440 /s/ Jennifer Martin By Jennifer Martin, Attorney-in-Fact for James N. Topper, pursuant to Power of Attorney 0001341382
Patrick J. Heron 12% 5,243,421 23,981 5,219,440 /s/ Jennifer Martin By Jennifer Martin, Attorney-in-Fact for Patrick J. Heron, pursuant to Power of Attorney 0001365617
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .